A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 294,600 shares of RAPT stock, worth $241,572. This represents 0.0% of its overall portfolio holdings.

Number of Shares
294,600
Previous 203,900 44.48%
Holding current value
$241,572
Previous $621,000 4.67%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.76 - $3.75 $159,632 - $340,125
90,700 Added 44.48%
294,600 $592,000
Q2 2024

Aug 09, 2024

BUY
$2.89 - $9.38 $306,051 - $993,342
105,900 Added 108.06%
203,900 $621,000
Q1 2024

May 13, 2024

BUY
$6.87 - $26.45 $673,260 - $2.59 Million
98,000 New
98,000 $880,000
Q2 2023

Aug 11, 2023

SELL
$16.06 - $21.61 $918,631 - $1.24 Million
-57,200 Reduced 52.72%
51,300 $959,000
Q1 2023

May 12, 2023

BUY
$17.19 - $30.8 $1.31 Million - $2.35 Million
76,200 Added 235.91%
108,500 $1.99 Million
Q4 2022

Feb 13, 2023

BUY
$16.28 - $24.6 $42,328 - $63,960
2,600 Added 8.75%
32,300 $640,000
Q3 2022

Nov 14, 2022

BUY
$17.96 - $30.46 $533,412 - $904,662
29,700 New
29,700 $715,000
Q2 2022

Aug 12, 2022

SELL
$10.26 - $23.59 $466,830 - $1.07 Million
-45,500 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$17.02 - $40.22 $452,732 - $1.07 Million
26,600 Added 140.74%
45,500 $1 Million
Q4 2021

Feb 11, 2022

SELL
$29.5 - $39.5 $569,350 - $762,350
-19,300 Reduced 50.52%
18,900 $694,000
Q3 2021

Nov 12, 2021

BUY
$29.86 - $39.47 $1.14 Million - $1.51 Million
38,200 New
38,200 $1.19 Million
Q1 2021

May 13, 2021

SELL
$16.0 - $24.46 $177,600 - $271,506
-11,100 Closed
0 $0
Q4 2020

Feb 10, 2021

BUY
$15.89 - $40.87 $176,379 - $453,657
11,100 New
11,100 $219,000

Others Institutions Holding RAPT

About RAPT Therapeutics, Inc.


  • Ticker RAPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,656,600
  • Market Cap $24.3M
  • Description
  • RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...
More about RAPT
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.